AUTHOR=Crook Timothy , Patil Darshana , Nagarkar Rajnish , Gaya Andrew , Plowman Nicholas , Limaye Sewanti , Srivastava Navin , Akolkar Dadasaheb , Ranade Anantbhushan , Bhatt Amit , Datta Vineet , Bose Chirantan , Apurwa Sachin , Patil Sanket , Kumar Prashant , Srinivasan Ajay , Datar Rajan 

TITLE=Angiogenesis Inhibitors in Personalized Combination Regimens for the Treatment of Advanced Refractory Cancers

JOURNAL=Frontiers in Molecular Medicine

VOLUME=1

YEAR=2021

URL=https://www.frontiersin.org/journals/molecular-medicine/articles/10.3389/fmmed.2021.749283

DOI=10.3389/fmmed.2021.749283

ISSN=2674-0095

ABSTRACT=<p><bold>Background:</bold> Angiogenic factors are commonly activated in solid tumors and present a viable therapeutic target. However, anticancer treatment with angiogenesis inhibitors (AGI) is limited to a few cancers, mostly as monotherapy and not selected based on molecular indications. We aimed to determine whether patient-specific combination regimens with AGI and other anticancer agents when selected based on multi-analyte tumor interrogation (ETA: Encyclopedic Tumor Analysis) can expand the scope of AGIs in advanced refractory solid organ cancers with improved treatment responses.</p><p><bold>Methods:</bold> We evaluated treatment outcomes in 60 patients with advanced, refractory solid organ cancers who received ETA-guided combination regimens of AGI with other targeted, endocrine or cytotoxic agents. Radiological evaluation of treatment response was followed by determination of Objective Response Rate (ORR), Disease Control Rate (DCR), Progression Free Survival (PFS) and Overall Survival (OS).</p><p><bold>Results:</bold> Among the 60 patients, Partial Response (PR) was observed in 28 cases (46.7%), Stable Disease (SD) was observed in 29 cases (48.3%) and Disease Progression (PD, within 60 days) was observed in 3 cases (5.0%). The ORR was 46.7% and DCR was 95.0%. At the most recent follow-up the median PFS (mPFS) was 5.0 months and median OS (mOS) was 8.9 months. There were no Grade 4 therapy related adverse events or treatment related deaths.</p><p><bold>Conclusion:</bold> ETA-guided patient-specific combination regimens with AGI and other anti-neoplastic agents, can yield improved outcomes over AGI monotherapy. Trial Registration: Details of all trials are available at WHO-ICTRP: <ext-link ext-link-type="uri" xlink:href="https://apps.who.int/trialsearch/" xmlns:xlink="http://www.w3.org/1999/xlink">https://apps.who.int/trialsearch/</ext-link>. RESILIENT ID CTRI/2018/02/011,808. LIQUID IMPACT ID CTRI/2019/02/017,548.</p>